1 junio 2015
An extensive literature review has found that side effects from regorafenib like redness and swelling may be undertreated. Also included in this study are recommendations from experienced oncologists and dermatologists that outline supportive measures to help prevent or reduce Hand-Foot-Skin-Reaction (HFSR) symptoms. Better management of HFSR may allow patients to continue to take regorafenib at an optimal dose.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/YyM3-CRHorE/150601104421.htm
